HSP90 Heat-Shock Proteins
"HSP90 Heat-Shock Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of MOLECULAR CHAPERONES whose members act in the mechanism of SIGNAL TRANSDUCTION by STEROID RECEPTORS.
| Descriptor ID |
D018841
|
| MeSH Number(s) |
D12.776.580.216.380
|
| Concept/Terms |
HSP90 Heat-Shock Proteins- HSP90 Heat-Shock Proteins
- HSP90 Heat Shock Proteins
- Heat-Shock Proteins, HSP90
- Heat-Shock Proteins 90
- Heat Shock Proteins 90
|
Below are MeSH descriptors whose meaning is more general than "HSP90 Heat-Shock Proteins".
Below are MeSH descriptors whose meaning is more specific than "HSP90 Heat-Shock Proteins".
This graph shows the total number of publications written about "HSP90 Heat-Shock Proteins" by people in this website by year, and whether "HSP90 Heat-Shock Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 1 | 3 |
| 1997 | 2 | 0 | 2 |
| 1998 | 1 | 0 | 1 |
| 1999 | 2 | 0 | 2 |
| 2000 | 2 | 1 | 3 |
| 2001 | 3 | 0 | 3 |
| 2002 | 1 | 0 | 1 |
| 2003 | 2 | 0 | 2 |
| 2004 | 2 | 0 | 2 |
| 2005 | 5 | 1 | 6 |
| 2006 | 1 | 0 | 1 |
| 2007 | 2 | 0 | 2 |
| 2008 | 1 | 0 | 1 |
| 2009 | 5 | 0 | 5 |
| 2010 | 4 | 0 | 4 |
| 2011 | 5 | 0 | 5 |
| 2012 | 2 | 1 | 3 |
| 2013 | 2 | 1 | 3 |
| 2014 | 1 | 1 | 2 |
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 3 | 1 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "HSP90 Heat-Shock Proteins" by people in Profiles.
-
Que NLS, Crowley VM, Duerfeldt AS, Zhao J, Kent CN, Blagg BSJ, Gewirth DT. Structure Based Design of a Grp94-Selective Inhibitor: Exploiting a Key Residue in Grp94 To Optimize Paralog-Selective Binding. J Med Chem. 2018 04 12; 61(7):2793-2805.
-
Khandelwal A, Kent CN, Balch M, Peng S, Mishra SJ, Deng J, Day VW, Liu W, Subramanian C, Cohen M, Holzbeierlein JM, Matts R, Blagg BSJ. Structure-guided design of an Hsp90ß N-terminal isoform-selective inhibitor. Nat Commun. 2018 01 30; 9(1):425.
-
Voruganti S, Kline JT, Balch MJ, Rogers J, Matts RL, Hartson SD. Proteomic Profiling of Hsp90 Inhibitors. Methods Mol Biol. 2018; 1709:139-162.
-
Davenport J, Galam L, Matts RL. A High-Throughput Screen for Inhibitors of the Hsp90-Chaperone Machine. Methods Mol Biol. 2018; 1709:87-96.
-
Lin SF, Lin JD, Hsueh C, Chou TC, Yeh CN, Chen MH, Wong RJ. Efficacy of an HSP90 inhibitor, ganetespib, in preclinical thyroid cancer models. Oncotarget. 2017 Jun 20; 8(25):41294-41304.
-
Sharma J, Pareek V, Liu H, Cheng H. Emerging treatment for ALK-positive lung cancer. Expert Opin Emerg Drugs. 2016 Jun; 21(2):147-55.
-
Floen MJ, Forred BJ, Bloom EJ, Vitiello PF. Thioredoxin-1 redox signaling regulates cell survival in response to hyperoxia. Free Radic Biol Med. 2014 Oct; 75:167-77.
-
Manjarrez JR, Sun L, Prince T, Matts RL. Hsp90-dependent assembly of the DBC2/RhoBTB2-Cullin3 E3-ligase complex. PLoS One. 2014; 9(3):e90054.
-
Sadikot T, Swink M, Eskew JD, Brown D, Zhao H, Kusuma BR, Rajewski RA, Blagg BS, Matts RL, Holzbeierlein JM, Vielhauer GA. Development of a high-throughput screening cancer cell-based luciferase refolding assay for identifying Hsp90 inhibitors. Assay Drug Dev Technol. 2013 Oct; 11(8):478-88.
-
Voruganti S, Lacroix JC, Rogers CN, Rogers J, Matts RL, Hartson SD. The anticancer drug AUY922 generates a proteomics fingerprint that is highly conserved among structurally diverse Hsp90 inhibitors. J Proteome Res. 2013 Aug 02; 12(8):3697-706.